Denver, CO — In interviews at ARVO 2026, Vinit Mahajan M.D., Ph.D., Stanford professor and vice chair for ophthalmology research, detailed the promising 3-year outcomes of Nanoscope’s MCO-010, an optogenetic gene therapy for advanced retinitis pigmentosa (RP). This novel, disease-agnostic therapy aims to restore vision by delivering a light-sensing opsin to bipolar cells, bypassing damaged photoreceptors. The long-term follow-up showed that a single injection resulted in clinically meaningful and sustained vision gains, corresponding to approximately 3 lines on an eye chart, without serious treatment-related adverse events. In a series of interviews, Dr. Mahajan discusses these results, the factors that predict treatment response, and the therapy's significance for the RP community. He also describes how this technology could be applied to other blinding eye diseases like macular degermation and Stargardt’s disease. Click the links to hear his interviews: Healio, Eye Care Network, Ophthalmology Times.